{"id":"W4394008906","doi":"10.1016/j.eururo.2024.03.015","title":"Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study","year":2024,"lang":"en","type":"article","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University of Alberta; McMaster University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Western University","funders":"National Cancer Institute; Genentech; European Society for Medical Oncology; Astellas Pharma; National Comprehensive Cancer Network; Eisai; Ipsen; BeiGene; Daiichi Sankyo Europe; Exelixis; Memorial Sloan-Kettering Cancer Center; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lenvatinib; Internal medicine; Confidence interval; Renal cell carcinoma; Pembrolizumab; Sunitinib; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Oncology; Phases of clinical research; Urology; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003783597,0.0001698598,0.0004079997,0.0003256804,0.00004603517,0.000007944464,0.0001898873,0.00002477633,0.00009755522],"category_scores_gemma":[0.00007432514,0.00009233255,0.0001120733,0.0009425734,0.0001025541,0.00003204043,0.0001664129,0.0001636837,0.00001446853],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009939519,"about_ca_system_score_gemma":0.00008148151,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002396841,"about_ca_topic_score_gemma":0.00006243274,"domain_scores_codex":[0.9975342,0.001102841,0.0004479897,0.0003719645,0.000352451,0.0001906121],"domain_scores_gemma":[0.9988622,0.0002063326,0.0001652835,0.0006072607,0.0001060805,0.00005283526],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09602898,0.002066164,0.8043084,0.00007204642,0.0007783817,0.0003916069,0.008111486,0.001232719,0.08436186,0.00001863519,0.00005323149,0.002576467],"study_design_scores_gemma":[0.006479266,0.00828894,0.9783319,0.00001363489,0.0009426156,0.00000337543,0.00008581274,0.0001492548,0.005132871,2.500152e-7,0.0004989133,0.00007318809],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972726,0.00006159915,0.00001824475,0.0002181903,0.00009143006,0.001035773,0.00008075606,0.0000145585,0.001206925],"genre_scores_gemma":[0.9987049,0.000002229647,0.00001246026,0.00008090581,0.00002881244,0.00001488192,0.000088497,0.00003455267,0.001032822],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1740235,"threshold_uncertainty_score":0.3765212,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02779521509965852,"score_gpt":0.2702784539642715,"score_spread":0.242483238864613,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}